WESTLAKE VILLAGE, CA – March 9, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, will showcase its ClearID Breast Cancer Total Insight Monitoring service at the 34th Annual Miami Breast Cancer Conference (Booth #11) in Miami Beach, FL, the Young Survival Coalition (YSC) Summit (Booth #29) in Oakland, and The 27th Annual Interdisciplinary Breast Center Conference (Booth #209) in Las Vegas, NV. The company is also a sponsor of the YSC Summit.
These important events kick off the launch of Cynvenio’s new ClearID Total Insight monitoring program for breast cancer, a service based on the company’s proprietary LiquidBiopsy technology. Conference attendees can visit Cynvenio to learn more about this new program and the benefits of ClearID Breast Cancer testing to support quick and accurate identification of tumor-related genetic mutations that can be treated with targeted therapies.
About the Conferences
34th Annual Miami Breast Cancer Conference®
March 9-12, 2017, Miami Beach, FL
The multidisciplinary conference brings together surgical, medical, and radiation oncologists, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging crossteam cooperation in the clinic. Pioneers of innovative approaches in each of these subspecialties will provide insight into the optimal multidisciplinary management of patients with breast cancer and its application to practice.
Young Survival Coalition Summit 2017
March 10-12, 2017, Oakland, CA
This national conference features the most up-to-date information about the unique needs of young women with breast cancer. Program includes inspirational speakers, educational workshops, wellness activities, and more.
The 27th Annual Interdisciplinary Breast Center Conference
March 11-15, 2017, Las Vegas, NV
The NCBC brings together medical and industry professionals from around the globe to network, learn and share ideas, methodologies and treatment options that improve quality of care and outcomes for patients diagnosed with breast diseases.
About Cynvenio Biosystems, Inc.
Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients. Among the company’s breakthroughs are its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California (Los Angeles). For more information, please visit www.cynvenio.com, www.clearidmonitoring.com and www.liquidbiopsy.com.
LiquidBiopsy® and ClearID®, are registered trademarks, and ClearID Breast Cancer Total Insight™ and NK-Score™ are trademarks, of Cynvenio Biosystems, Inc.